Achaogen (AKAOQ) Inactive 10-Q2017 Q1 Quarterly report

Filed: 8 May 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: accredited, adapt, AIA, antimicrobial, attrition, Century, Clause, coli, composite, congressional, contemplated, Counsel, District, Dorling, draft, endpoint, environment, enzyme, eradication, ERP, Escherichia, essential, exceeded, exploit, Fisher, freeze, Friedland, Gary, heightened, House, Hovione, Ian, ill, incremental, ingredient, inter, interacting, IPR, Janet, Klebsiella, lactam, lactamase, Loeb, LPAD, Melinda, membrane, mMITT, modernize, molecule, move, moved, neglected, neonatal, neutrality, nil, Notably, NSP, occasionally, OMB, oral, outer, passage, pathogen, persuade, petition, poverty, preliminary, Premarket, presidential, pressure, proof, quantity, ready, reap, reclassified, reconciliation, redemption, reinstated, repeal, repealed, replenished, requisite, resale, rolling, rulemaking, run, scale, Senate, spur, statistical, sum, susceptibility, Thermo, tradeable, twelve, unclear, uncured, underwritten, unfold, unused, visit, wholly, workforce

Removed: accuracy, AG, animal, attain, automatic, backup, biodefense, Blake, burden, canceled, carbapenem, companion, comparator, comparison, conservative, conserve, converted, costlier, demonstrating, dissuade, division, dosage, doubt, Dr, engine, ESBL, exhibit, explanatory, explicit, fast, fluoroquinolone, footnote, goal, greatest, Hillan, implantable, inclusion, inflammation, infusion, Kenneth, lab, legally, levofloxacin, meeting, necessitate, October, Oxford, pharmacodynamic, pharmacokinetic, predicate, projected, published, recommend, regimen, release, reliably, resultant, revise, revocation, satisfactory, Select, shift, Silicon, sought, spectrum, spending, Suisse, superior, track, trend, trillion, unfeasible, University, USA, Valley, varying, vivo, Washington, Wise, withdrew

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

AKAOQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Achaogen, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended March 31, 2017, as filed with the Securities and Exchange Commission (the “Report”), Kenneth J. Hillan, Chief Executive Officer of the Company, and Tobin C. Schilke, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2017

/s/ Kenneth J. Hillan

Kenneth J. Hillan

Chief Executive Officer

(principal executive officer)

/s/ Tobin C. Schilke

Tobin C. Schilke

Chief Financial Officer

(principal financial and accounting officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.